Wealthfront Advisers LLC Purchases New Position in Kura Oncology, Inc. (NASDAQ:KURA)

Wealthfront Advisers LLC purchased a new stake in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 147,943 shares of the company's stock, valued at approximately $1,289,000. Wealthfront Advisers LLC owned about 0.19% of Kura Oncology at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. AlphaQuest LLC acquired a new stake in Kura Oncology in the 4th quarter valued at about $177,000. E Fund Management Co. Ltd. acquired a new stake in Kura Oncology in the 4th quarter valued at about $90,000. Charles Schwab Investment Management Inc. lifted its holdings in Kura Oncology by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 635,494 shares of the company's stock valued at $5,535,000 after acquiring an additional 10,542 shares during the last quarter. US Bancorp DE lifted its holdings in Kura Oncology by 184.5% in the 4th quarter. US Bancorp DE now owns 22,104 shares of the company's stock valued at $193,000 after acquiring an additional 14,335 shares during the last quarter. Finally, Rhumbline Advisers lifted its holdings in Kura Oncology by 2.0% in the 4th quarter. Rhumbline Advisers now owns 99,991 shares of the company's stock valued at $871,000 after acquiring an additional 1,923 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Scotiabank cut their price target on shares of Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a report on Wednesday, January 8th. BTIG Research downgraded Kura Oncology from a "buy" rating to a "neutral" rating in a report on Thursday, February 6th. Wedbush restated an "outperform" rating and set a $36.00 price objective on shares of Kura Oncology in a report on Thursday, February 27th. UBS Group cut their price objective on Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Finally, Jefferies Financial Group cut their price objective on Kura Oncology from $32.00 to $28.00 and set a "buy" rating on the stock in a report on Thursday, November 21st. Three analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $25.50.

Remove Ads

Insider Activity

In related news, SVP Thomas James Doyle sold 4,949 shares of the business's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares of the company's stock, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Mollie Leoni sold 4,963 shares of the business's stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the sale, the insider now directly owns 88,253 shares of the company's stock, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock worth $92,307 in the last 90 days. Company insiders own 5.50% of the company's stock.

Kura Oncology Stock Up 0.7 %

Shares of KURA traded up $0.05 during trading hours on Tuesday, reaching $7.34. The company's stock had a trading volume of 1,021,294 shares, compared to its average volume of 1,057,433. The firm has a market cap of $592.74 million, a price-to-earnings ratio of -3.11 and a beta of 0.85. Kura Oncology, Inc. has a 1-year low of $6.79 and a 1-year high of $23.48. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a 50 day moving average of $7.82 and a two-hundred day moving average of $12.65.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million. As a group, research analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.